US FDA approves Denali's genetic disorder therapy
25/03/2026 15:41
March 25 (Reuters) - The U.S. Food and Drug Administration has approved Denali Therapeutics' DNLI.O therapy for a rare genetic disorder, the regulator said on Wednesday. (Reporting by Kunal Das and Sneha S K; Editing by Jonathan Ananda) ((Kunal.Das2@thomsonreuters.com;))
Recent news on Denali Therapeutics
See all newsDenali Therapeutics Inc. reports results for the quarter ended June 30 - Earnings Summary
Denali Therapeutics Q2 net loss widens as AVLAYAH launch costs rise
Biogen's Alzheimer's drug lowers toxic protein, but results were mixed
U.S. STOCKS ON THE MOVE-Sweetgreen, Dell Technologies, Peloton Interactive
U.S. STOCKS ON THE MOVE-IMAX, Novo Nordisk, PC makers